Updates are available Correction dated 2025-10-29
Click to view Correction: https://doi.org/10.1007/s00415-025-13483-5
-
Authors
Lanz, Thomas A. https://orcid.org/0000-0003-2483-3122
Ruprecht, Klemens
Somps, Christopher J.
Göpfert, Jens C.
Kam-Thong, Tony
Tekle, Fetene
Fader, Kelly A.
Yañez, Viviana A. Carcamo
Meyer, Volker
Friedrich, Sabine
Vlasakova, Katerina
Otto, Carolin
Paciga, Sara A.
Samodelov, Sophia L.
Ramaiah, Shashi K.
-
Funding
Funding for this research was provided by:
Innovative Medicines Initiative (821283)
- License Information
-
More Information
Article History
Received: 4 April 2025
Revised: 30 June 2025
Accepted: 2 July 2025
First Online: 15 July 2025
Change Date: 29 October 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00415-025-13483-5
Declarations
:
: TAL, CJS, KAF, SAP, and SKR were employees of Pfizer Inc., KV was an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., FT was an employee of Johnson & Johnson, and TK-T was an employee of Roche Pharma at the time this work was performed. KR received research support from Novartis, Merck Serono, German Ministry of Education and Research, European Union (821283–2), Stiftung Charité, Guthy-Jackson Charitable Foundation and Arthur Arnstein Foundation; received travel grants from Guthy-Jackson Charitable Foundation; received speaker’s honoraria from Virion Serion and Novartis; was a participant in the BIH Clinical Fellow Program funded by Stiftung Charité. This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 821283. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and EFPIA companies.
